Imatinib might constitute a treatment option for lung involvement in COVID-19.
作者信息
Bernal-Bello David, Jaenes-Barrios Beatriz, Morales-Ortega Alejandro, Ruiz-Giardin José Manuel, García-Bermúdez Virginia, Frutos-Pérez Begoña, Farfán-Sedano Ana Isabel, de Ancos-Aracil Cristina, Bermejo Fernando, García-Gil Mario, Zapatero-Gaviria Antonio, San Martín-López Juan Víctor
机构信息
Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid, Spain..
Castilla La Nueva Primary Health Care Center, Madrid, Spain..
出版信息
Autoimmun Rev. 2020 Jul;19(7):102565. doi: 10.1016/j.autrev.2020.102565. Epub 2020 May 3.
Abstract
摘要
相似文献
1
Imatinib might constitute a treatment option for lung involvement in COVID-19.伊马替尼可能构成COVID-19肺部受累的一种治疗选择。
Autoimmun Rev. 2020 Jul;19(7):102565. doi: 10.1016/j.autrev.2020.102565. Epub 2020 May 3.
2
Why judiciously timed anti-IL 6 therapy may be of benefit in severe COVID-19 infection.为何适时进行的抗白细胞介素6治疗可能对重症COVID-19感染有益。
Autoimmun Rev. 2020 Jul;19(7):102563. doi: 10.1016/j.autrev.2020.102563. Epub 2020 May 5.
3
Cytokine storm syndrome in severe COVID-19.重症新型冠状病毒肺炎中的细胞因子风暴综合征
Autoimmun Rev. 2020 Jul;19(7):102562. doi: 10.1016/j.autrev.2020.102562. Epub 2020 May 3.
4
Extracorporeal cytokine adsorption as an alternative to pharmacological inhibition of IL-6 in COVID-19.体外细胞因子吸附作为COVID-19中白细胞介素-6药物抑制的替代方法。
Crit Care. 2020 Aug 20;24(1):514. doi: 10.1186/s13054-020-03238-1.
5
Complement Inhibition in Coronavirus Disease (COVID)-19: A Neglected Therapeutic Option.冠状病毒病（COVID-19）中的补体抑制：一种被忽视的治疗选择。
Front Immunol. 2020 Jul 7;11:1661. doi: 10.3389/fimmu.2020.01661. eCollection 2020.
6
Inhibiting IL-6 in COVID-19: we are not sure.在新冠肺炎中抑制白细胞介素-6：我们并不确定。
Crit Care. 2020 Jul 27;24(1):463. doi: 10.1186/s13054-020-03177-x.
7
IL-6 may be a good biomarker for earlier detection of COVID-19 progression.白细胞介素-6可能是早期检测新型冠状病毒肺炎病情进展的良好生物标志物。
Intensive Care Med. 2020 Jul;46(7):1475-1476. doi: 10.1007/s00134-020-06065-8. Epub 2020 May 8.
8
Brief annotations on cytokine release syndrome and interleukin-6 therapeutic blockage in SARS-CoV-2/COVID-19.关于细胞因子释放综合征及白细胞介素-6治疗性阻断在严重急性呼吸综合征冠状病毒2/冠状病毒病中的简要注释
Arch Cardiol Mex. 2020;90(Supl):84-87. doi: 10.24875/ACM.M20000067.
9
Interleukin-17: A potential therapeutic target in COVID-19.白细胞介素-17：新冠病毒病的一个潜在治疗靶点。
J Infect. 2020 Aug;81(2):e136-e138. doi: 10.1016/j.jinf.2020.05.072. Epub 2020 Jun 3.
10
Predicting Severe Outcomes in COVID-19.预测新冠病毒病的严重后果
J Allergy Clin Immunol Pract. 2020 Sep;8(8):2582-2584. doi: 10.1016/j.jaip.2020.06.039. Epub 2020 Jun 29.
引用本文的文献
1
Imatinib decreases germ cell survival and germline stem cell proliferation in rodent testis ex vivo and in vitro.伊马替尼在体外和体内均可降低啮齿动物睾丸中的生殖细胞存活率和生殖系干细胞增殖率。
Andrology. 2025 Sep;13(6):1575-1591. doi: 10.1111/andr.13777. Epub 2024 Oct 18.
2
Impact of Imatinib on reducing the painful crisis in patients with sickle cell disease.伊马替尼对降低镰状细胞病患者疼痛危象的影响。
Hematol Transfus Cell Ther. 2024 Oct-Dec;46(4):387-392. doi: 10.1016/j.htct.2023.06.007. Epub 2023 Aug 10.
3
Targeting Inflammation in Non-Small Cell Lung Cancer through Drug Repurposing.通过药物再利用靶向非小细胞肺癌中的炎症
Pharmaceuticals (Basel). 2023 Mar 16;16(3):451. doi: 10.3390/ph16030451.
4
In silico investigation of the therapeutic and prophylactic potential of medicinal substances bearing guanidine moieties against COVID-19.含胍基部分的药用物质对 COVID-19 治疗和预防潜力的计算机模拟研究
Chem Zvesti. 2023;77(2):1129-1148. doi: 10.1007/s11696-022-02528-y. Epub 2022 Oct 21.
5
-Volume II: Immunity Following Infection or mRNA Vaccination, Drug Therapies and Non-Pharmacological Management at Post-Two Years SARS-CoV-2 Pandemic.第二卷：SARS-CoV-2 大流行两年后感染或 mRNA 疫苗接种、药物治疗和非药物管理后的免疫。
Medicina (Kaunas). 2022 Feb 17;58(2):309. doi: 10.3390/medicina58020309.
6
Drug-Induced Liver Disturbance During the Treatment of COVID-19.新型冠状病毒肺炎治疗期间的药物性肝损伤
Front Pharmacol. 2021 Aug 18;12:719308. doi: 10.3389/fphar.2021.719308. eCollection 2021.
7
COVID-19 Pandemic: Advances in Diagnosis, Treatment, Organoid Applications and Impacts on Cancer Patient Management.2019冠状病毒病大流行：诊断、治疗、类器官应用进展及对癌症患者管理的影响
Front Med (Lausanne). 2021 Mar 29;8:606755. doi: 10.3389/fmed.2021.606755. eCollection 2021.
8
COVID-19 in patients with hematological malignancies: Considering the role of tyrosine kinase inhibitors.血液系统恶性肿瘤患者中的新型冠状病毒肺炎：考虑酪氨酸激酶抑制剂的作用
Cancer. 2021 Jun 1;127(11):1937-1938. doi: 10.1002/cncr.33432. Epub 2021 Mar 15.
9
COVID-19, cytokines, inflammation, and spices: How are they related?新型冠状病毒肺炎、细胞因子、炎症与香料：它们之间有何关联？
Life Sci. 2021 Nov 1;284:119201. doi: 10.1016/j.lfs.2021.119201. Epub 2021 Feb 16.
10
Review of pharmacologic and immunologic agents in the management of COVID-19.新型冠状病毒肺炎治疗中药物及免疫制剂的综述
Biosaf Health. 2021 Jun;3(3):148-155. doi: 10.1016/j.bsheal.2021.01.001. Epub 2021 Jan 9.
本文引用的文献
1
Corona (COVID-19) time musings: Our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planning.新冠（COVID-19）时期的思考：我们在新冠病毒致病机制、诊断、治疗及疫苗研发计划中的参与情况
Autoimmun Rev. 2020 Jun;19(6):102538. doi: 10.1016/j.autrev.2020.102538. Epub 2020 Apr 5.
2
The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease.细胞因子（包括白细胞介素 6）在 COVID-19 诱导性肺炎和巨噬细胞活化综合征样疾病中的作用。
Autoimmun Rev. 2020 Jun;19(6):102537. doi: 10.1016/j.autrev.2020.102537. Epub 2020 Apr 3.
3
COVID-19: consider cytokine storm syndromes and immunosuppression.2019冠状病毒病：考虑细胞因子风暴综合征和免疫抑制。
Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.
4
The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status.2019 冠状病毒病（COVID-19）疫情的起源、传播和临床治疗——现状更新。
Mil Med Res. 2020 Mar 13;7(1):11. doi: 10.1186/s40779-020-00240-0.
5
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).羟氯喹治疗严重急性呼吸综合征冠状病毒 2 （SARS-CoV-2）的体外抗病毒活性和优化剂量设计预测。
Clin Infect Dis. 2020 Jul 28;71(15):732-739. doi: 10.1093/cid/ciaa237.
6
A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option.洛匹那韦疗法治疗严重急性呼吸综合征冠状病毒和中东呼吸综合征冠状病毒的系统评价——为新型冠状病毒病治疗方案提供参考。
J Med Virol. 2020 Jun;92(6):556-563. doi: 10.1002/jmv.25729. Epub 2020 Mar 12.
7
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease.巴瑞替尼作为2019新型冠状病毒急性呼吸道疾病的潜在治疗方法。
Lancet. 2020 Feb 15;395(10223):e30-e31. doi: 10.1016/S0140-6736(20)30304-4. Epub 2020 Feb 4.
8
Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding.新冠病毒的基因组特征和流行病学：对病毒起源和受体结合的影响。
Lancet. 2020 Feb 22;395(10224):565-574. doi: 10.1016/S0140-6736(20)30251-8. Epub 2020 Jan 30.
9
Imatinib stimulates prostaglandin E and attenuates cytokine release via EP4 receptor activation.伊马替尼通过激活EP4受体刺激前列腺素E并减弱细胞因子释放。
J Allergy Clin Immunol. 2019 Feb;143(2):794-797.e10. doi: 10.1016/j.jaci.2018.09.030. Epub 2018 Oct 16.
10
Imatinib mesylate use in refractory eosinophilic granulomatosis with polyangiitis: a literature review and a case report.甲磺酸伊马替尼治疗难治性嗜酸性肉芽肿伴多血管炎：文献回顾及病例报告。
Clin Rheumatol. 2018 Jun;37(6):1729-1735. doi: 10.1007/s10067-018-4018-1. Epub 2018 Mar 21.
Zotero 插件